Valuation dashboard for Genmab A/S (GMAB) with P/E 43.75, P/B 5.77, EV/EBITDA 27.2 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses.
Analysis Summary
Genmab A/S reported revenue of $3.72B in the most recent fiscal year, growing at a 5-year CAGR of -18.1%. Net income reached $963.8M, with a -27.3% 5-year CAGR.
Trailing-twelve-month margins: gross margin 39.9%, operating margin 13.8%, net margin 8.2%.
At $55.52 (closing price, November 3, 2026), GMAB trades at a P/E of 43.75 and an ROE of 13.58%. Market capitalisation stands at $34.1B, placing it among large-cap names.
Balance sheet quality for GMAB: debt-to-equity ratio of 0.89, current ratio of 2.46 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 43.75 |
| Price / Book | 5.77 |
| EV / EBITDA | 27.2 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GMAB | Genmab A/S | $34.1B | 43.75 | 5.77 | 13.6% |
| BNTX | BioNTech SE | $21.8B | 1.13 | -9.2% | |
| INCY | Incyte Corporation | $24.0B | 62.55 | 4.24 | 7.1% |
| EXEL | Exelixis, Inc. | $18.2B | 21.65 | 9.73 | 45.5% |
| LEGN | Legend Biotech Corporation | $4.0B | 3.27 | -8.7% | |
| IOVA | Iovance Biotherapeutics, Inc. | $4.0B | 5.40 | -40.5% | |
| RCUS | Arcus Biosciences, Inc. | $2.4B | 5.24 | -88.0% |
Price
| Price | $55.52 (closing price, November 3, 2026) |
| Market Cap | $34.1B |
| Exchange | NASDAQ |
| Country | DK |
Profitability
| Return on Equity | 13.58% |
| Return on Invested Capital | 9.91% |
| Return on Assets | 6.30% |
| Gross Margin | 39.92% |
| Operating Margin | 13.81% |
| Net Margin | 8.17% |
Related companies: BNTX · INCY · EXEL · LEGN · IOVA · RCUS
Explore sector: Healthcare · Biotechnology
More sections of GMAB: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks